Authors
Latest:
Face-Off: Award Presentation CeremonyFollowing a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.
Latest:
Impact of T-cell Affinity in Bispecific Therapy in R/R MMNoopur Raje, MD, discusses the role of T-cell affinity in bispecific therapy for patients with relapsed/refractory multiple myeloma and how it impacts treatment practices.
Latest:
Current Frontline Treatment of Diffuse Large B-Cell LymphomaThis review article discusses which frontline treatment are best for diffuse large B-cell lymphoma.
Latest:
Life After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple MyelomaLife After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple Myeloma
Latest:
Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary InfectionThis case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.
Latest:
Clinical Implications and Future DirectionsPanelists discuss how pembrolizumab plus lenvatinib has established a new benchmark and become the preferred first-line treatment option for more than 95% of patients with non–clear cell renal cell carcinoma (RCC), according to national guidelines, demonstrating activity across all major histological subtypes despite the heterogeneous nature of these diseases, while acknowledging that specific rare histologies may still require tailored approaches.
Latest:
Immune Modulation in Sarcoma: Targeting the Tumor MicroenvironmentExplore the latest advancements in sarcoma immunotherapy, focusing on tumor microenvironment modulation and innovative treatment strategies for improved patient outcomes.
Latest:
How Can Lower-Income Countries Maintain Representation in Clinical Trials?Lower- and middle-income countries must work to build trust with pharmaceutical companies to enhance representation in cancer-related clinical trials.
Latest:
Radiation Oncology Remains ‘Third Leg of the Stool’ in Cancer Treatment, But Continues to Be SuccessfulThe emergence of using hypofractionated radiation treatments—fewer radiation treatments at larger doses—across cancer types may place financial strain on radiation oncologists, but one expert notes there’s still continued success.
Latest:
Decisional Capacity Determination in Patients With CancerExperts discuss the process of assessing decision-making capacity in patients with cancer.
Latest:
Expert Reviews Alternative Treatment Options in Muscle-Invasive Bladder CancerShilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
Latest:
Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple MyelomaInvestigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.
Latest:
Omidubicel Can ‘Improve Outcomes’ in Blood Cancer Needing UCB TransplantCorey Cutler, MD, MPH, FRCPC, discusses how patients with blood cancer in need of an umbilical cord blood transplant may benefit from omidubicel-onlv.
Latest:
Leveraging Novel Software to Further Improve Personalized Cancer CareA novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Latest:
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETsRead about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
Latest:
Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid LeukemiaInvestigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
